Literature DB >> 20624774

Incidence of renal replacement therapy (RRT) in the diabetic compared with the non-diabetic population in a German region, 2002-08.

Andrea Icks1, Burkhard Haastert, Jutta Genz, Guido Giani, Falk Hoffmann, Rudolf Trapp, Michael Koch.   

Abstract

BACKGROUND: This study was conducted to estimate incidences of renal replacement therapy (RRT) in the diabetic and non-diabetic populations in Germany, as well as relative and attributable risks of RRT due to diabetes.
METHODS: Using the data of a regional dialysis centre (region population of 310 000), we assessed all incident RRT patients aged 30 years or older in 2002-08. We estimated sex- and age-specific and -standardized incidences of RRT in the diabetic and non-diabetic populations, which were estimated by applying diabetes prevalences from a population-based study, and relative and attributable risks due to diabetes.
RESULTS: Of all subjects with incident RRT (n = 544), 49.6% had diabetes. Fifty-eight percent were male, mean age (SD) was 70.3 years (11.4 years). Incidences per 100 000 person-years (standardized to the 2004 German population) in the diabetic and the non-diabetic populations were 213.7 [95% confidence interval (95% CI), 159.5-267.8] and 26.9 (95% CI, 22.5-31.3) in men and 130.2 (95% CI, 65.6-194.9) and 16.4 (95% CI, 13.5-19.3) in women, respectively. Standardized relative risks were 7.9 (5.9-10.8) in men and 8.0 (4.7-13.5) in women. There was a significant interaction between age and diabetes, with lower relative risks in higher ages. Attributable risks among diabetic individuals were 0.87 in men and women, and population-attributable risks were 0.41 and 0.35 in men and women, respectively.
CONCLUSIONS: In this population-based study in a German region, we found the relative risk of RRT in the estimated adult diabetic population to be 8-fold increased compared with the non-diabetic population. A high proportion of the RRT risk can be attributed to diabetes in the diabetic as well as in the whole population.

Entities:  

Mesh:

Year:  2010        PMID: 20624774     DOI: 10.1093/ndt/gfq398

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN: 0931-0509            Impact factor:   5.992


  6 in total

1.  Development of the simulation-based German albuminuria screening model (S-GASM) for estimating the cost-effectiveness of albuminuria screening in Germany.

Authors:  Paul Kairys; Thomas Frese; Paul Voigt; Johannes Horn; Matthias Girndt; Rafael Mikolajczyk
Journal:  PLoS One       Date:  2022-01-05       Impact factor: 3.240

2.  Incidence and relative risk of renal replacement therapy in people with and without diabetes between 2002 and 2016 in a German region.

Authors:  Maria Narres; Heiner Claessen; Tatjana Kvitkina; Michael Koch; Lars Christian Rump; Thomas Weinreich; Andrea Icks
Journal:  Diabetologia       Date:  2019-12-21       Impact factor: 10.122

3.  End-stage renal disease and survival in people with diabetes: a national database linkage study.

Authors:  S Bell; E H Fletcher; I Brady; H C Looker; D Levin; N Joss; J P Traynor; W Metcalfe; B Conway; S Livingstone; G Leese; S Philip; S Wild; N Halbesma; N Sattar; R S Lindsay; J McKnight; D Pearson; H M Colhoun
Journal:  QJM       Date:  2014-08-19

4.  Social inequality and diabetes mellitus - developments over time among the adult population in Germany.

Authors:  Christin Heidemann; Yong Du; Jens Baumert; Rebecca Paprott; Thomas Lampert; Christa Scheidt-Nave
Journal:  J Health Monit       Date:  2019-06-27

5.  Study design of DIACORE (DIAbetes COhoRtE) - a cohort study of patients with diabetes mellitus type 2.

Authors:  Lena Dörhöfer; Alexander Lammert; Vera Krane; Mathias Gorski; Bernhard Banas; Christoph Wanner; Bernhard K Krämer; Iris M Heid; Carsten A Böger
Journal:  BMC Med Genet       Date:  2013-02-14       Impact factor: 2.103

Review 6.  The Incidence of End-Stage Renal Disease in the Diabetic (Compared to the Non-Diabetic) Population: A Systematic Review.

Authors:  Maria Narres; Heiner Claessen; Sigrid Droste; Tatjana Kvitkina; Michael Koch; Oliver Kuss; Andrea Icks
Journal:  PLoS One       Date:  2016-01-26       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.